Biopharmaceutical Success Depends on Delivery, Fueling $7.8 BN Market: Report
NEW YORK, Nov. 16, 2018
NEW YORK, Nov. 16, 2018 /PRNewswire-PRWeb/ -- A promising new product can flounder if patients don't comply, and companies are thinking about delivery systems that can improve compliance early in the development of new drugs. Market research firm Kalorama Information said that the total market for biopharmaceutical drug delivery devices is estimated at $7.8 billion, boosted by developments in implants, pumps, and microfluidics, as well as needle-free injectors. That's according to a new report from Kalorama, World Market for Biopharmaceutical Drug Delivery Device Technology. https://www.kaloramainformation.com/Biopharmaceutical-Drug-Delivery-Device-Technology-12013625/.
Kalorama said that nearly 70% of drugs approved for the marketplace this year will be the result of biotechnology. It's the area of fastest revenue growth in the pharmaceutical industry, growing at an average rate of 12%-15% over the past two years. Sales of select biopharmaceuticals have been brisk: Enbrel $7.8 billion, Remicade $8.1billion, Humira $18.6 billion, and Avastin $6.8 billion for 2017. The continued expansion of biotechnology and gene therapy has resulted in an increased use of proteins, peptides, and genes in the treatment of diseases, where delivery strategies are challenging and critical.
"A new biopharmaceutical may be a potential blockbuster but if it does not have an easy patient-friendly delivery method, that potential will not be realized, because there will be compliance problems," said Bruce Carlson, Publisher of Kalorama Information. "Biopharma is looking at user-friendly pens, jets, patches and other systems to enhance their compliance and breathe new life into their existing products."
Pfizer, for instance, is a leading provider of needle-free drug delivery technology for vaccines. The company offers the Particle Mediated Epidermal Delivery (PMED) technology, a needle- free delivery system that delivers DNA-coated microscopic gold particles into the skin using pressurized helium gas.
"The use of this technology in both prophylactic and therapeutic vaccines has had a substantial impact on Pfizer's growing market share," Carlson said.
Needle-free is a significant area of development covered in Kalorama's report. To reduce the risk of needle-stick injuries, needle-free admixture systems can be packaged in the kit with the biotherapeutic and prefilled syringe. To improve speed to market for these systems, a number of contract manufacturing companies have established their own diluent syringe master files that can be referenced by the pharmaceutical company buyer. Because patients' compliance may be increased with seamless self-administration of injectables, other improvement to drug delivery technology includes the use of autoinjectors and cartridge pens. For biologics, the time to market with a prefilled syringe is shorter than in a vial form.
Kalorama Information's report provides market sizing and forecasting for several categories of drug delivery, sorts out the competitive advantages of various delivery improvements, and makes forecasts for revenues earned by delivery device providers. The report also covers companies who specialized in delivery. The report is available at: https://www.kaloramainformation.com/Biopharmaceutical-Drug-Delivery-Device-Technology-12013625/
About Kalorama Information
Kalorama Information, a division of BioInformatics Inc., supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website: https://www.kaloramainformation.com/.